Page 2274 - Williams Hematology ( PDFDrive )

2248 Part XII: Hemostasis and Thrombosis Chapter 131: The Antiphospholipid Syndrome 2249

199. Gibson GE, Su WP, Pittelkow MR: Antiphospholipid syndrome and the skin. J Am Acad 233. Lipp E, von-Felten A, Sax H, Muller D, Berchtold P: Antibodies against platelet gly-
Dermatol 36:970–982, 1997. coproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J
200. Asherson RA, Cervera R: The antiphospholipid syndrome: Multiple faces beyond the Haematol 60:283–288, 1998.
classical presentation. Autoimmun Rev 2:140–151, 2003. 234. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al: Antiphospholipid antibodies and
201. Aronoff DM, Callen JP: Necrosing livedo reticularis in a patient with recurrent pulmo- antiphospholipid syndrome in patients presenting with immune thrombocytopenic
nary hemorrhage. J Am Acad Dermatol 37:300–302, 1997. purpura: A prospective cohort study. Blood 98:1760–1764, 2001.
202. Greco TP, Conti-Kelly AM, Matsuura E, et al: Antiphospholipid antibodies in patients 235. Vivaldi P, Rossetti G, Galli M, Finazzi G: Severe bleeding due to acquired hypoproth-
with coronary artery disease: New cardiac risk factors? Ann N Y Acad Sci 1108:466–474, rombinemia-lupus anticoagulant syndrome. Case report and review of literature.
2007. Haematologica 82:345–347, 1997.
203. Vaarala O: Antiphospholipid antibodies and myocardial infarction. Lupus 7(Suppl 2): 236. Hudson N, Duffy CM, Rauch J, Paquin JD, Esdaile JM: Catastrophic haemorrhage in a
S132–S134, 1998. case of paediatric primary antiphospholipid syndrome and factor II deficiency. Lupus
204. Sherer Y, Shoenfeld Y: Antiphospholipid antibodies: Are they pro-atherogenic or an 6:68–71, 1997.
epiphenomenon of atherosclerosis? Immunobiology 207:13–16, 2003. 237. Dunn JP, Noorily SW, Petri M, et al: Antiphospholipid antibodies and retinal vascular
205. Ludia C, Domenico P, Monia C, et al: Antiphospholipid antibodies: A new risk factor disease. Lupus 5:313–322, 1996.
for restenosis after percutaneous transluminal coronary angioplasty? Autoimmunity 238. Coniglio M, Platania A, Di Nucci GD, et al: Antiphospholipid-protein antibodies are
27:141–148, 1998. not an uncommon feature in retinal venous occlusions. Thromb Res 83:183–188, 1996.
206. Chambers-JD J, Haire HD, Deligonul U: Multiple early percutaneous transluminal 239. Glacet BA, Bayani N, Chretien P, et al: Antiphospholipid antibodies in retinal vascular
coronary angioplasty failures related to lupus anticoagulant. Am Heart J 132:189–190, occlusions. A prospective study of 75 patients. Arch Ophthalmol 112:790–795, 1994.
1996. 240. Dori D, Gelfand YA, Brenner B, Miller B: Cilioretinal artery occlusion: An ocular com-
207. Ames PR, Antinolfi I, Scenna G, et al: Atherosclerosis in thrombotic primary antiphos- plication of primary antiphospholipid syndrome. Retina 17:555–557, 1997.
pholipid syndrome. J Thromb Haemost 7:537–542, 2009. 241. Reino S, Munoz RF, Cervera R, et al: Optic neuropathy in the “primary” antiphospho-
208. Niaz A, Butany J: Antiphospholipid antibody syndrome with involvement of a biopros- lipid syndrome: Report of a case and review of the literature. Clin Rheumatol 16:629–
thetic heart valve. Can J Cardiol 14:951–954, 1998. 631, 1997.
209. Bouillanne O, Millaire A, de Groote P, et al: Prevalence and clinical significance of 242. Au A, O’Day J: Review of severe vaso-occlusive retinopathy in systemic lupus erythe-
antiphospholipid antibodies in heart valve disease: A case-control study. Am Heart matosus and the antiphospholipid syndrome: Associations, visual outcomes, complica-
J 132:790–795, 1996. tions and treatment. Clin Experiment Ophthalmol 32:87–100, 2004.
210. Nesher G, Ilany J, Rosenmann D, Abraham AS: Valvular dysfunction in antiphospho- 243. Fakhouri F, Noel LH, Zuber J, et al: The expanding spectrum of renal diseases associ-
lipid syndrome: Prevalence, clinical features, and treatment. Semin Arthritis Rheum ated with antiphospholipid syndrome. Am J Kidney Dis 41:1205–1211, 2003.
27:27–35, 1997. 244. Nochy D, Daugas E, Droz D, et al: The intrarenal vascular lesions associated with pri-
211. Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart valve involvement (Libman-Sacks mary antiphospholipid syndrome. J Am Soc Nephrol 10:507–518, 1999.
endocarditis) in the antiphospholipid syndrome. Circulation 93:1579–1587, 1996. 245. Breda L, Nozzi M, De SS, Chiarelli F: Laboratory tests in the diagnosis and follow-up of
212. Bulckaen HG, Puisieux FL, Bulckaen ED, et al: Antiphospholipid antibodies and the risk pediatric rheumatic diseases: An update. Semin Arthritis Rheum 40:53–72, 2010.
of thromboembolic events in valvular heart disease. Mayo Clin Proc 78:294–298, 2003. 246. Avcin T, Cimaz R, Silverman ED, et al: Pediatric antiphospholipid syndrome:
213. Ziporen L, Goldberg I, Arad M, et al: Libman-Sacks endocarditis in the antiphospho- Clinical and immunologic features of 121 patients in an international registry. Pediatrics
lipid syndrome: Immunopathologic findings in deformed heart valves. Lupus 5:196– 122:e1100–e1107, 2008.
205, 1996. 247. Falcini F, Taccetti G, Ermini M, Trapani S, Matucci CM: Catastrophic antiphospho-
214. Lee RW, Taylor-LM J, Landry GJ, et al: Prospective comparison of infrainguinal bypass lipid antibody syndrome in pediatric systemic lupus erythematosus. J Rheumatol 24:
grafting in patients with and without antiphospholipid antibodies. J Vasc Surg 24:524– 389–392, 1997.
531, 1996. 248. Ol’binskaia LI, Poptsov VN, Gofman AM: [Hemodynamic changes in patients with
215. Porres-Aguilar M, Pena-Ruiz MA, Burgos JD, et al: Chronic thromboembolic pulmo- myocardial infarct complicated by acute left ventricular failure during combined nitro-
nary hypertension as an uncommon presentation of primary antiphospholipid syn- glycerin and dobutamine therapy] [in Russian]. Kardiologiia 31:49–51, 1991.
drome. J Natl Med Assoc 100:734–736, 2008. 249. Boffa MC, Lachassinne E: Infant perinatal thrombosis and antiphospholipid antibod-
216. Karmochkine M, Cacoub P, Dorent R, et al: High prevalence of antiphospholipid anti- ies: A review. Lupus 16:634–641, 2007.
bodies in precapillary pulmonary hypertension. J Rheumatol 23:286–290, 1996. 250. Motta M, Chirico G, Rebaioli CB, et al: Anticardiolipin and anti-beta2 glycoprotein I
217. Bonderman D, Wilkens H, Wakounig S, et al: Risk factors for chronic thromboembolic antibodies in infants born to mothers with antiphospholipid antibody-positive autoim-
pulmonary hypertension. Eur Respir J 33:325–331, 2009. mune disease: A follow-up study. Am J Perinatol 23:247–251, 2006.
218. Asherson RA: The catastrophic antiphospholipid syndrome, 1998. A review of the clin- 251. Mekinian A, Lachassinne E, Nicaise-Roland P, et al: European registry of babies born to
ical features, possible pathogenesis and treatment. Lupus 7(Suppl 2):S55–S62, 1998. mothers with antiphospholipid syndrome. Ann Rheum Dis 72:217–222, 2013.
219. Uthman I, Khamashta M: The abdominal manifestations of the antiphospholipid syn- 252. Brewster JA, Shaw NJ, Farquharson RG: Neonatal and pediatric outcome of infants
drome. Rheumatology (Oxford) 46:1641–1647, 2007. born to mothers with antiphospholipid syndrome. J Perinat Med 27:183–187, 1999.
220. Biron C, Andreani H, Blanc P, et al: Prevalence of antiphospholipid antibodies in 253. Nacinovich R, Galli J, Bomba M, et al: Neuropsychological development of chil-
patients with chronic liver disease related to alcohol or hepatitis C virus: Correlation dren born to patients with antiphospholipid syndrome. Arthritis Rheum 59:345–351,
with liver injury. J Lab Clin Med 131:243–250, 1998. 2008.
221. Sene D, Piette JC, Cacoub P: Antiphospholipid antibodies, antiphospholipid syndrome 254. Marie I, Levesque H, Heron F, et al: Acute adrenal failure secondary to bilateral infarc-
and infections. Autoimmun Rev 7:272–277, 2008. tion of the adrenal glands as the first manifestation of primary antiphospholipid anti-
222. Ramos-Casals M, Cervera R, Lagrutta M, et al: Clinical features related to antiphospho- body syndrome. Ann Rheum Dis 56:567–568, 1997.
lipid syndrome in patients with chronic viral infections (hepatitis C virus/HIV infec- 255. Espinosa G, Santos E, Cervera R, et al: Adrenal involvement in the antiphospho-
tion): Description of 82 cases. Clin Infect Dis 38:1009–1016, 2004. lipid syndrome: Clinical and immunologic characteristics of 86 patients. Medicine
223. Hoffman M, Burke M, Fried M, et al: Primary biliary cirrhosis associated with anti- (Baltimore) 82:106–118, 2003.
phospholipid syndrome. Isr J Med Sci 33:681–686, 1997. 256. Paydas S, Kocak R, Zorludemir S, Baslamisli F: Bone marrow necrosis in antiphospho-
224. Date K, Shirai Y, Hatakeyama K: Antiphospholipid antibody syndrome presenting as lipid syndrome. J Clin Pathol 50:261–262, 1997.
acute acalculous cholecystitis. Am J Gastroenterol 92:2127–2128, 1997. 257. Pengo V, Tripodi A, Reber G, et al: Update of the guidelines for measuring the presence
225. Dessailloud R, Papo T, Vaneecloo S, et al: Acalculous ischemic gallbladder necrosis in of Lupus Anticoagulant. J Thromb Haemost 7:1737–1740, 2009.
the catastrophic antiphospholipid syndrome. Arthritis Rheum 41:1318–1320, 1998. 258. de Groot PG, Derksen RH, de LB: Twenty-two years of failure to set up undisputed
226. Kalman DR, Khan A, Romain PL, Nompleggi DJ: Giant gastric ulceration associated assays to detect patients with the antiphospholipid syndrome. Semin Thromb Hemost
with antiphospholipid antibody syndrome. Am J Gastroenterol 91:1244–1247, 1996. 34:347–355, 2008.
227. Gul A, Inanc M, Ocal L, et al: Primary antiphospholipid syndrome associated with 259. Favaloro EJ: Variability and diagnostic utility of antiphospholipid antibodies including
mesenteric inflammatory veno-occlusive disease. Clin Rheumatol 15:207–210, 1996. lupus anticoagulants. Int J Lab Hematol 35:269–274, 2013.
228. Lee HJ, Park JW, Chang JC: Mesenteric and portal venous obstruction associated with 260. Mateo J, Oliver A, Borrell M, et al: Laboratory evaluation and clinical characteristics
primary antiphospholipid antibody syndrome. J Gastroenterol Hepatol 12:822–826, of 2,132 consecutive unselected patients with venous thromboembolism—results of
1997. the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost
229. Galli M, Finazzi G, Barbui T: Thrombocytopenia in the antiphospholipid syndrome. Br 77:444–451, 1997.
J Haematol 93:1–5, 1996. 261. Naarendorp M, Spiera H: Sudden sensorineural hearing loss in patients with systemic
230. Cuadrado MJ, Mujic F, Munoz E, Khamashta MA, Hughes GR: Thrombocytopenia in lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies. J Rheu-
the antiphospholipid syndrome. Ann Rheum Dis 56:194–196, 1997. matol 25:589–592, 1998.
231. Macchi L, Rispal P, Clofent SG, et al: Anti-platelet antibodies in patients with systemic 262. Galli M, Luciani D, Bertolini G, Barbui T: Anti-beta 2-glycoprotein I, antiprothrombin
lupus erythematosus and the primary antiphospholipid antibody syndrome: Their rela- antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood
tionship with the observed thrombocytopenia. Br J Haematol 98:336–341, 1997. 102:2717–2723, 2003.
232. Pierrot-Deseilligny DC, Michel M, Khellaf M, et al: Antiphospholipid antibodies in 263. Shah NM, Khamashta MA, Atsumi T, Hughes GR: Outcome of patients with anticardi-
adults with immune thrombocytopenic purpura. Br J Haematol 142:638–643, 2008. olipin antibodies: A 10 year follow-up of 52 patients. Lupus 7:3–6, 1998.

Kaushansky_chapter 131_p2233-2252.indd 2249 9/18/15 5:10 PM